MRTX Mirati Therapeutics Inc.

74.67
+1.44  (+2%)
Previous Close 73.23
Open 73.52
Price To Book 13.05
Market Cap 2633431767
Shares 35,267,601
Volume 246,930
Short Ratio
Av. Daily Volume 701,943

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 biomarker analysis presented at SITC November 2018.
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
Phase 2 update at SITC November 2018 - 5/29 partial responses.
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 initial data 1H 2019.
Sitravatinib
Renal cell carcinoma (RCC)
Phase 3 trial to be initiated 1H 2019 with interim analysis YE 2020, final data YE 2021.
Sitravatinib
Non-small cell lung cancer (NSCLC)
Phase 1b initial data due 2H 2019.
Sitravatinib and tislelizumab
Solid tumors
Phase 1/2 patient dosing has commenced - January 15, 2019.
MRTX849
Solid tumors
Phase 2 initial data 2H 2019.
Sitravatinib
Urothelial Carcinoma (Bladder)

Latest News

  1. Mirati Therapeutics To Present At Upcoming Healthcare Conferences
  2. Mirati Therapeutics Reports Fourth Quarter Financial Results
  3. Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital — Research Highlights Growth, Revenue, and Consolidated Results
  4. Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors
  5. Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
  6. Here's Why Mirati Therapeutics Jumped 55.8% in January
  7. Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics
  8. How Many Insiders Sold Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares?
  9. The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
  10. Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
  11. The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
  12. Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
  13. Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
  14. Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
  15. Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics
  16. Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause
  17. Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%
  18. Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
  19. Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
  20. Mirati Therapeutics Added To NASDAQ Biotechnology Index